B
reast cancer is a leading cause of cancer-related death found in women worldwide, with a steadily increasing incidence in many countries over the past 30 years. [1] [2] [3] [4] Thus, early detection and thorough evaluation of primary breast cancer and its metastases may lead to a higher rate of successful treatment and extend the patient's life span.
Currently, the diagnosis of breast cancer is usually determined using anatomical imaging, such as x-ray mammography, ultrasound (US), and MRI, and is confirmed via biopsy. With the advent of molecular imaging, nuclear medicine techniques are considered to hold promise for the early detection of tumors through a functional perspective, providing information on molecular characteristics.
The gastrin-releasing peptide receptor (GRPR) is known as a G-protein-coupled receptor that is expressed in a series of cancer types, including breast cancer, small cell lung cancer, prostate cancer, glioma, and neuroblastoma. [5] [6] [7] [8] According to literature, 62% to 96% of primary breast cancers express GRPR. Gastrin-releasing peptide receptor is heterogeneously expressed in neoplastic epithelial mammary cells, ductal carcinomas in situ, and invasive carcinoma. Gastrin-releasing peptide receptor is also expressed in metastatic lymph nodes from breast cancer, whereas the level of GRPR expression in normal lymph node tissue is very low. 6, 9 Gastrin-releasing peptide receptor exhibited a predominantly intracytoplasmic expression in breast tumor cells and with concomitant immunoreactivity of the cell membrane. Recent studies have shown a preference for GRPR antagonists over GRPR agonists. 10, 11 Compared with receptor agonists, antagonists often show higher binding and more favorable pharmacokinetics. 12 The GRPR antagonist RM26 (D-Phe-Gln-Trp-Ala-Val-GlyHis-Sta-Leu-NH 2 ) was synthesized and conjugated to NOTA chelator via a short PEG spacer and labeled with 68 Ga. Tumor targeting and biodistribution studies of 68 Ga-NOTA-RM26 in mice bearing PC-3 human prostate cancer xenografts showed high and specific uptake in tumors and a high tumor-to-background ratio. 13 More recently, we proved that 68 Ga-NOTA-RM26 PET/CT was safe and useful in patients with prostate cancer.
14 However, its use in the assessment of breast cancer has not been systemically explored. Thus, here, we evaluated the diagnostic value of PET/CT using 68 Ga-NOTA-RM26 for patients with suspicious breast lesions as a pilot study to verify its usefulness.
PATIENTS AND METHODS

Patients
This study was registered at clinicaltrials.gov (NCT03347864). With institutional review board approval and written informed consent, 35 women suspected of having 36 primary breast cancers based on mammography or ultrasonography and not having experienced any local or systemic therapies were recruited from November 2016 to April 2018 in Peking Union Medical College Hospital. The average patient age (mean ± standard deviation) was 49 ± 11 years (range, 30-71 years). Among the patients, 23 were premenopausal women with regular menstrual cycles, and the remaining 12 patients were postmenopausal women. The menstrual status was recorded on the day of performing 68 Ga-NOTA-RM26 PET/CT in premenopausal women. The patients' basic characteristics are listed in Table 1 .
68
Ga-NOTA-RM26 PET/CT Preparation of NOTA-RM26 and 68 Ga labeling was performed as described previously. 13 All patients underwent 68 Ga-NOTA-RM26 PET/CT acquisitions from upper thigh to chin using a Biograph 64 Truepoint TrueV TrueX system (Siemens Medical Solutions, Erlangen, Germany) at 30 minutes after intravenous injection of 1.85 MBq (0.05 mCi) per kilogram body weight of 68 Ga-NOTA-RM26 within 1 week before the surgery. The images from upper thigh to chin were acquired using a low-dose CT scan (120 kV, 35 mA, 512 Â 512 matrix, 3-mm layer, and 70 cm field of view). The PET scan of each patient covered in 5 to 6 bed positions (2 minutes per bed), with the arms held above the head and from the upper thigh to chin.
Immunohistochemistry
We examined the immunohistochemical features of the obtainable specimens in 20 of 35 cases. Estrogen receptor (ER), progesterone receptor (PR), and HER-2 status were determined according to published recommendations. 15, 16 The representative samples of excised tumors and lymph nodes were fixed with 10% neutral buffered formalin and embedded in paraffin. Four-micrometer-thick tissue slices were incubated with rabbit antihuman polyclonal antibody against human GRPR (ab39963) after blocking and washing. Immunohistochemistry results for GRPR were independently evaluated by 2 experienced examiners and expressed as an immunoreactive score (IRS) in consideration of staining intensity (0, no staining; 1, weak staining; 2, moderate staining; and 3, strong staining) and the percentage of positive tumor cells (0, no positive cells; 1, ≤10% positive cells; 2, 11%-50% positive cells; 3, 51%-80% positive cells; and 4, >80% positive cells). Therefore, the final IRS score (staining intensity Â percentage of positive cells) was in the range of 0 to 12. For the purpose of our study, no GRPR expression means IRS 0-1, weak GRPR expression means IRS 2-3, moderate GRPR expression refers to IRS 4-8, and strong GRPR expression refers to IRS 9-12.
PET/CT Image and Data Analysis
The PET/CT images were manipulated on a Siemens MMWP workstation. PET images were jointly analyzed by 2 experienced nuclear medicine physicians. For 68 Ga-NOTA-RM26 PET/CT imaging, PET positivity was defined as focal tracer uptake of the primary tumor or lymph nodes over the local background, in correlation with CT. The tumors with uptakes similar to or lower than breast tissue were defined as PET negative. The maximum and mean standardized uptake values (SUVmax and SUVmean, respectively) in the volumes of interest were acquired through the software. The tumor-to-background (T/B) ratios were calculated for further analysis. The peripheral breast tissue was considered as background for calculation.
Statistical Analysis
Calculations were performed using SPSS software (IBM SPSS Statistics for Windows, Version 21.0; Armonk, NY). All quantitative data were expressed as mean ± standard deviation. A P < 0.05 was accepted as statistically significant. SUV values were correlated with ER, human epidermal growth factor receptor 2 (Her-2), PR status, and the Ki-67 index in univariate analysis (Spearman rho [ρ] for ordinal/continuous and t test for nominal data). One-way analysis of variance was used to analyze the correlation of 68 Ga-NOTA-RM26 uptake in breast tissue with the menstrual cycle. The correlation between PET positivity with ER status and the menstrual cycle was evaluated using χ 2 test. Receiver operating characteristic (ROC) curve analysis was performed to determine an optimal cutoff for detecting breast cancer and breast tissue and to compare the diagnostic performance when the ER-negative patients or those in the secretory phase were removed. Furthermore, correlation analysis used the Spearman rank correlation test between the SUV values and the IRs.
RESULTS
In the 35 patients, a total of 36 tumors were verified by surgery and pathology, including 27 invasive ductal cancer, 1 invasive lobular carcinoma, 4 intraductal carcinoma, 1 lobular carcinoma in situ, 1 mucinous carcinoma, and 2 fibroadenoma. Among the 34 lesions with breast cancer, 28 tumors were ER positive, 27 tumors were PR positive, and 29 tumors were in different level of Her-2 positivity. Eighteen patients were pathologically reported with ipsilateral lymph node metastasis, and 3 patients only reported with micro-metastasis. No remarkable adverse event (dizziness, vomiting, abdominal discomfort) correlated with the study was reported in any of the enrolled patients within 2 hours after the administration. Ga-NOTA-RM26 uptake as compared with the normal breast tissue and were rated as PET positive (Figs. 1-3) . The SUVmax of PET-positive tumors was from 2.07 to 9.01 (4.88 ± 1.92), and the T/B ratios were from 1.62 to 17.09 (3.27 ± 2.82). Three tumors that could not be differentiated from breast tissue and two tumors that showed 68 Ga-NOTA-RM26 accumulation lower than the breast tissue were diagnosed as PET negative (Fig. 4) . The SUVmax of 68 Ga-NOTA-RM26 activity in PET-negative tumors was from 2.10 to 3.64 (2.94 ± 0.56), and the T/B ratios of 68 Ga-NOTA-RM26 accumulation were from 0.71 to 1.38 (1.08 ± 0.29). The SUVmax of 68 Ga-NOTA-RM26 activity in all 34 breast cancers was 4.58 ± 1.93. The 2 fibroadenomas could not be distinguished from the surrounding breast tissue and were thus defined as PET negative. The SUVmax of the corresponding regions were 3.48 and 1.94, respectively.
PET positivity was associated with ER status (P = 0.006). Twenty-six of 28 tumors with positive ER expression were diagnosed with PET positive, in contast to 3 of 6 tumors with ER-negative expression rated PET positive. The SUVmax in ER-positive tumors was 4.97 ± 1.89 as compared with 2.78 ± 0.65 in ER-negative tumors (P < 0.001) (Fig. 5A) . However, no correlations were found between SUV max and the other relative biomarker expressions (ie, PR, Her-2 status, and Ki-67 in percent).
The breast tissue showed intraindividual and interindividual variability, moderately strong 68 Ga-NOTA-RM26 binding, with an SUVmax of 0.55 to 3.22 (1.80 ± 0.68) and an SUVmean of 0.35 to 2.66 (1.18 ± 0.56). The intensity of 68 Ga-NOTA-RM26 uptake in the breast tissue was significantly associated with the menstrual cycle (P = 0.002 for SUVmax, and P = 0.001 for SUVmean). Physiologic RM26 uptake in the breast tissue in patients at secretory phase (SUVmax 2.27 ± 0.71, n = 14) was significantly higher than those at the nonsecretory phase (SUV max 1.59 ± 0.49, n = 10; P = 0.017) and postmenopause (SUV max 1.43 ± 0.44, n = 12; Clinical Nuclear Medicine • Volume 43, Number 9, September 2018 68 Ga-NOTA-RM26 PET/CT in Breast Cancer P = 0.002). Moreover, PET positivity was also associated with menstrual cycle (P = 0.019). Four of 5 tumors rated PET negative were examined during the secretory phase. In addition, the uterus showed 68 Ga-NOTA-RM26 uptake with moderate to intense densities in all phases of the menstrual cycle and postmenopause, with an SUVmax of 2.88 to 9.23 (5.01 ± 1.80) and an SUVmean of 1.71 to 7.94 (3.18 ± 1.42).
The ROC curve analysis showed that the area under the curve for 68 Ga-NOTA-RM26 uptake level was 0.952 in breast tumor and breast tissue for the breast cancer patients. Optimal diagnostic cutoff value according to ROC analysis was 2.76. When an SUVmax of 2.76 was used as a cutoff, the resulting sensitivity, specificity, and accuracy were 85.3%, 86.8%, and 86.1%, respectively. Ga-NOTA-RM26 PET, CT, and fusion image. The SUVmax of the tumor was 9.01, and the SUVmax of normal breast tissue was only 0.55). Note that the metastatic lymph node in diameter of 6 mm could also be visualized (arrowhead) with elevated 68 Ga-NOTA-RM26 uptake with SUVmax of 1.2 (E-G). The tumor was stained positively for E4R (H) and GRPR (I). The lymph node was also stained positively for GRPR (J). Ga-NOTA-RM26 PET, CT, and fusion image. The SUVmax of the tumor was 2.66, and the SUVmax of normal breast tissue was 2.98). The tumor was stained negatively for GRPR (E) and ER (F), and normal breast tissue was stained positively for GRPR (G). Ga-RM26 PET; C and F, CT; D and G, fusion images). The SUVmax of the right breast tumor, metastatic lymph nodes, and normal breast tissue were 4.47, 16.14, and 2.20, respectively. An occult lesion was also found on the left breast, but the patient rejected further surgery, and the lesion is still under follow-up.
